DURHAM, N.C., October 30, 2018 — Angi Robinson, Executive Director for Rare Disease and Pediatrics at Premier Research, will discuss clinical development strategies for genetic rare disease research November 7 at the World Orphan Drug Congress in Barcelona.
Ms. Robinson’s presentation, starting at 2:20 p.m., will examine management of confirmatory testing and specialty labs, the role of related patients, and lessons learned from development of therapies to treat genetic rare diseases. Topics will include:
- Study design considerations such as inclusion and exclusion criteria and the role of siblings and other relatives
- Weighing safety vs. efficacy, data handling, special patient populations, and other operational issues
- Finding patients: When does it make sense to create a special screening test?
For more information, visit https://www.terrapinn.com/conference/world-orphan-drug-congress/speaker-angi-ROBINSON.stm.
About Premier Research
Premier Research is a leading clinical development service provider that helps biotech and specialty pharma innovators — small companies with big ambitions — transform life-changing ideas into new medicines. The company applies a relentless focus on quality in the execution of global, regional, and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical devices, neuroscience, oncology, pediatrics, and rare disease. Premier Research operates in 84 countries and employs 1,300 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that transform breakthrough biotech thinking into reality.